myelodysplastic syndromes (MDS) - Articles and news items

Encouraging top-line results for APG101 in myelodysplastic syndromes

Industry news / 15 June 2016 / Victoria White, Digital Content Producer

A Phase I trial showed that APG101 was well tolerated. In addition, the study showed that APG101 efficiently stimulates erythropoiesis in these patients…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+